RESPONSE TO IV LIDOCAINE PREDICT FAVORABLE RESPONSE TO ORAL MEXILETIE

试验患者于1997年7月28日入院并入组研究， 1997年7月30日出院从这个试点开始，进行了一些修改， 以确保更顺畅地运行协议。 解决的问题 包括添加活性安慰剂，因为试点患者没有 难以确定研究的安慰剂阶段。 这双- 盲法交叉设计是一种改进， JCCI。 此外，还安排了研究药物 提供预混研究药物的服务，以确保 对我们的研究医生设盲并简化方案。 的 研究药物服务提供了一个区组随机化时间表， 也 四名输液患者已跟随试点患者参与 在这项研究中（11月之前总共有4个， 已完成）。 患者继续入组后 截肢疼痛输注研究。

The Pilot patient was admitted and enrolled into the study 7/28/97 and discharged 7/30/97. From this pilot, some revisions took place in order to ensure a smoother running protocol. Issues that were worked on included the addition of an active placebo, as the pilot patient had no difficulty in identifying the placebo phase of the study. This double- blinded cross-over design was an improvement and was approved by the JCCI. Also, arrangements were made with the Investigational Drug Service to provide the study medications pre-mixed as to ensure the blinding of our study physician and to streamline the protocol. The Investigational Drug Service provided a block randomization schedule, as well. Four infusion patients have followed the pilot patient in participating in this study (a total of 4 prior to November, a total of 8 have been completed to date). Patients continue to be enrolled into the Post Amputation Pain Infusion Study.